Literature DB >> 17262820

RECK expression in osteosarcoma: correlation with matrix metalloproteinases activation and tumor invasiveness.

Hyun-Guy Kang1, Han-Soo Kim, Kap-Jung Kim, Joo Han Oh, Mi-Ra Lee, So Mi Seol, Ilkyu Han.   

Abstract

Osteosarcoma is a malignant tumor of bone characterized by its high metastatic potential. For the development of metastasis, activation of matrix metalloproteinases (MMPs) is required. A novel MMPs inhibitor, reversion inducing cysteine rich protein with Kazal motifs (RECK), is known to down-regulate MMPs and suppress the invasive and metastatic potential in many tumor-derived cell lines and some types of tumors. The expression of RECK and its role in tumor invasiveness have never been studied in osteosarcoma. We examined RECK mRNA expression and MMPs activation in osteosarcoma using quantitative real time PCR, gelatin zymography, invasion assay, and transfection experiments. RECK was expressed but down-regulated in osteosarcoma cells. Activation of pro-MMP-2 was observed in all samples, whereas activation of MMP-2 and pro-MMP-9 was detected in only 11% and 7% of the samples, respectively. MMP-9 was not activated in any of the samples. The level of RECK expression was inversely correlated with pro-MMP-2 activation, and overexpression of RECK by transfection resulted in decreased pro-MMP-2 activation and reduced tumor invasiveness. These findings suggest that RECK plays an important role in the invasiveness of osteosarcoma. (c) 2007 Orthopaedic Research Society.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17262820     DOI: 10.1002/jor.20323

Source DB:  PubMed          Journal:  J Orthop Res        ISSN: 0736-0266            Impact factor:   3.494


  25 in total

1.  The metalloproteinase inhibitor Reck is essential for zebrafish DRG development.

Authors:  Andrew Prendergast; Tor H Linbo; Tanya Swarts; Josette M Ungos; Hillary F McGraw; Shlomo Krispin; Brant M Weinstein; David W Raible
Journal:  Development       Date:  2012-02-01       Impact factor: 6.868

2.  Estrogen suppresses expression of the matrix metalloproteinase inhibitor reversion-inducing cysteine-rich protein with Kazal motifs (RECK) within the mouse uterus.

Authors:  Xuan Zhang; Caitlin Healy; Warren B Nothnick
Journal:  Endocrine       Date:  2012-08       Impact factor: 3.633

Review 3.  Bone microenvironment signals in osteosarcoma development.

Authors:  Arantzazu Alfranca; Lucia Martinez-Cruzado; Juan Tornin; Ander Abarrategi; Teresa Amaral; Enrique de Alava; Pablo Menendez; Javier Garcia-Castro; Rene Rodriguez
Journal:  Cell Mol Life Sci       Date:  2015-05-03       Impact factor: 9.261

4.  MicroRNA-21 is involved in osteosarcoma cell invasion and migration.

Authors:  Wu Ziyan; Yang Shuhua; Weng Xiufang; Liu Xiaoyun
Journal:  Med Oncol       Date:  2010-05-18       Impact factor: 3.064

5.  Biomarkers in Osteosarcoma.

Authors:  Colin Kong; Marc F Hansen
Journal:  Expert Opin Med Diagn       Date:  2009-01-01

6.  Promoter hypermethylation of the cysteine protease RECK may cause metastasis of osteosarcoma.

Authors:  Leisheng Wang; Junbo Ge; Tian Ma; Yanpin Zheng; Shiqiao Lv; Yu Li; Shaoxian Liu
Journal:  Tumour Biol       Date:  2015-07-01

7.  Expression of RECK and matrix metalloproteinase-2 in ameloblastoma.

Authors:  Bin Zhang; Jin Zhang; Zhi-Ying Xu; Hong-Liang Xie
Journal:  BMC Cancer       Date:  2009-12-08       Impact factor: 4.430

8.  Reversion-inducing cysteine-rich protein with kazal motifs and matrix metalloproteinase-9 are prognostic markers in skull base chordomas.

Authors:  Nunung Nur Rahmah; Keiichi Sakai; Jun Nakayama; Kazuhiro Hongo
Journal:  Neurosurg Rev       Date:  2009-10-28       Impact factor: 3.042

Review 9.  A review of clinical and molecular prognostic factors in osteosarcoma.

Authors:  Jonathan C M Clark; Crispin R Dass; Peter F M Choong
Journal:  J Cancer Res Clin Oncol       Date:  2007-10-27       Impact factor: 4.553

10.  Regulation of cell invasion and signalling pathways in the pituitary adenoma cell line, HP-75, by reversion-inducing cysteine-rich protein with kazal motifs (RECK).

Authors:  Daizo Yoshida; Ryutaro Nomura; Akira Teramoto
Journal:  J Neurooncol       Date:  2008-05-21       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.